The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Open accessAbstract
BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma. METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma. Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy. The primary end point was the overall response rate. Secondary end points were duration of response, progression-free survival, overall survival, and safety. RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clinical prognostic factors. Patients had received a median of three prior therapies. The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea. Grade 3 or higher hematologic events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%). A response rate of 68% (75 patients) was observed, with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate. With an estimated median follow-up of 15.3 months, the estimated median response duration was 17.5 months (95% confidence interval [CI], 15.8 to not reached), the estimated median progression-free survival was 13.9 months (95% CI, 7.0 to not reached), and the median overall survival was not reached. The estimated rate of overall survival was 58% at 18 months. CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy.”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Self-citationOptimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,456
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,651
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Self-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.2307/2281868 · DOI · Paper page
Cited by
Sorted by citations
Items 101–200 of 1,000
Song, Y., Zhou, K., Zou, D., Zhou, J., Hu, J., Yang, H., Zhang, H., Ji, J., Xu, W., Jin, J., et al. (2022) · Blood · doi:10.1182/blood.2021014162 · Cited by 178
Novel agents in the treatment of multiple myeloma: a review about the future
Naymagon, L., & Abdul‐Hay, M. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0282-1 · Cited by 180
Management of adverse effects/toxicity of ibrutinib
Paydaş, S. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.001 · Cited by 178
Lipsky, A. H., Farooqui, M. Z. H., Tian, X., Martyr, S. E., Cullinane, A., Nghiem, K., Sun, C., Valdez, J., Niemann, C. U., Herman, S. E. M., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.126672 · Cited by 178
de Claro, R. A., McGinn, K. M., Verdun, N. C., Lee, S., Chiu, H.-J., Saber, H., Brower, M. E., Chang, C., Fletcher, E. P., Habtemariam, B. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2225 · Cited by 175
Mantle cell lymphoma: evolving management strategies
Campo, E., & Rule, S. A. (2014) · Blood · doi:10.1182/blood-2014-05-521898 · Cited by 174
Self-citationRule, S. A., Dreyling, M. H., Goy, A. H., Heß, G., Auer, R. L., Kahl, B. S., Hernández‐Rivas, J., Qi, K., Deshpande, S. V., Parisi, L., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.205229 · Cited by 171
Self-citationBruton tyrosine kinase degradation as a therapeutic strategy for cancer
Dobrovolsky, D., Wang, E. S., Morrow, S., Leahy, C., Faust, T., Nowak, R. P., Donovan, K. A., Yang, G., Li, Z., Fischer, E. S., et al. (2019) · Blood · doi:10.1182/blood-2018-07-862953 · Cited by 169
Camicia, R., Winkler, H. C., & Hassa, P. O. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0474-2 · Cited by 177
Syk inhibitors in clinical development for hematological malignancies
Liu, D., & Mamorska-Dyga, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0512-1 · Cited by 175
Non-Hodgkin’s Lymphomas, Version 4.2014
Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N. L., Byrd, J. C., Czuczman, M. S., Fayad, L., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0125 · Cited by 165
Self-citationPathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma
Saba, N. S., Liu, D., Herman, S. E. M., Underbayev, C., Tian, X., Behrend, D., Weniger, M. A., Skarzynski, M., Gyamfi, J., Fontán, L., et al. (2016) · Blood · doi:10.1182/blood-2015-11-681460 · Cited by 173
Wiczer, T. E., Levine, L. B., Brumbaugh, J., Coggins, J., Zhao, Q., Ruppert, A. S., Rogers, K. A., McCoy, A., Mousa, L., Guha, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009720 · Cited by 164
Self-citationDreyling, M. H., Doorduijn, J. K., Giné, E., Jerkeman, M., Walewski, J. A., Hutchings, M., Mey, U., Riise, J., Trněný, M., Vergote, V., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00184-3 · Cited by 164
Self-citationDelfau‐Larue, M., Hiddemann, W., Berger, F., Jardin, F., Brière, J., Salles, G. A., Casasnovas, O., Feugier, P., Haïoun, C., Ribrag, V., et al. (2015) · Blood · doi:10.1182/blood-2015-02-628792 · Cited by 162
Self-citationIbrutinib: First Global Approval
Cameron, F., & Sanford, M. (2014) · Drugs · doi:10.1007/s40265-014-0178-8 · Cited by 163
Current and future therapies for primary Sjögren syndrome
Seror, R., Nocturne, G., & Mariette, X. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00634-x · Cited by 138
Secondary mutations as mediators of resistance to targeted therapy in leukemia
Daver, N. G., Cortes, J. E., Ravandi, F., Patel, K. P., Burger, J. A., Konopleva, M. Y., & Kantarjian, H. M. (2015) · Blood · doi:10.1182/blood-2014-10-605808 · Cited by 164
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Bartlett, N. L., Costello, B. A., LaPlant, B. R., Ansell, S. M., Kuruvilla, J. G., Reeder, C. B., Thye, L. S., Anderson, D. M., Krysiak, K., Ramirez, C. A., et al. (2017) · Blood · doi:10.1182/blood-2017-09-804641 · Cited by 161
Alu, A., Lei, H., Han, X., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01353-w · Cited by 159
Jain, P., & Wang, M. L. (2022) · American Journal of Hematology · doi:10.1002/ajh.26523 · Cited by 156
Self-citationJerkeman, M., Eskelund, C. W., Hutchings, M., Räty, R., Wader, K. F., Laurell, A., Toldbod, H., Pedersen, L. B., Niemann, C. U., Dahl, C., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30018-8 · Cited by 154
Roit, F. D., Engelberts, P. J., Taylor, R. P., Breij, E. C. W., Gritti, G., Rambaldi, A., Introna, M., Parren, P. W. H. I., Beurskens, F. J. M., & Golay, J. (2014) · Haematologica · doi:10.3324/haematol.2014.107011 · Cited by 152
Sun, Y., Ding, N., Song, Y., Yang, Z., Liu, W., Zhu, J., & Rao, Y. (2019) · Leukemia · doi:10.1038/s41375-019-0440-x · Cited by 148
Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
Parikh, K., Cang, S., Sekhri, A., & Liu, D. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0078-0 · Cited by 148
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
Zhao, X., Lwin, T., Silva, A., Shah, B. D., Tao, J., Fang, B., Zhang, L., Fu, K., Li, J., Li, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14920 · Cited by 154
Self-citationIbrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance
Shi, Y., Guryanova, O. A., Zhou, W., Liu, C., Huang, Z., Fang, X., Wang, X., Chen, C., Wu, Q., He, Z., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aah6816 · Cited by 150
Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., O'Brien, S., & James, D. F. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1309710 · Cited by 150
Drug-perturbation-based stratification of blood cancer
Dietrich, S., Oleś, M., Lu, J., Sellner, L., Anders, S., Velten, B., Wu, B., Hüllein, J., Liberio, M. D. S., Walther, T., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93801 · Cited by 151
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
Stephens, D. M., & Byrd, J. C. (2019) · Blood · doi:10.1182/blood-2018-11-846808 · Cited by 148
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse
Bernard, S., Goldwirt, L., Amorim, S., Brice, P., Brière, J., de Kerviler, É., Mourah, S., Sauvageon, H., & Thiéblemont, C. (2015) · Blood · doi:10.1182/blood-2015-05-647834 · Cited by 149
Proteogenomic integration reveals therapeutic targets in breast cancer xenografts
Huang, K., Li, S., Mertins, P., Cao, S., Gunawardena, H. P., Ruggles, K. V., Mani, D. R., Clauser, K. R., Tanioka, M., Usary, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14864 · Cited by 152
Robak, T., Jin, J., Pylypenko, H., Verhoef, G. E. G., Siritanaratkul, N., Drach, J. W., Raderer, M., Mayer, J., Pereira, J. C., Tumyan, G. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30685-5 · Cited by 148
Kluin‐Nelemans, H. C., Hoster, E., Hermine, O., Walewski, J. A., Geisler, C. H., Trněný, M., Stilgenbauer, S., Kaiser, F., Doorduijn, J. K., Salles, G. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01294 · Cited by 145
Self-citationRule, S. A., Dreyling, M. H., Goy, A. H., Heß, G., Auer, R. L., Kahl, B. S., Cavazos, N., Liu, B., Yang, S., Clow, F., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14870 · Cited by 144
Self-citationScheers, E. M., Leclercq, L., de Jong, J., Bode, N., Bockx, M., Laenen, A., Cuyckens, F., Skee, D. M., Murphy, J., Sukbuntherng, J., et al. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.060061 · Cited by 144
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
de Weerdt, I., Koopmans, S. M., Kater, A. P., & van Gelder, M. (2017) · Haematologica · doi:10.3324/haematol.2017.164103 · Cited by 146
Eyre, T. A., Walter, H. S., Iyengar, S., Follows, G., Cross, M., Fox, C. P., Hodson, A., Coats, J. T., Narat, S., Morley, N. J., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.198812 · Cited by 142
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
Robak, P. J., & Robak, T. (2019) · Drugs in R&D · doi:10.1007/s40268-019-0269-9 · Cited by 147
BTK Signaling in B Cell Differentiation and Autoimmunity
Corneth, O. B. J., Wolterink, R. G. J. K., & Hendriks, R. W. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_478 · Cited by 145
Advances in targeted therapy for malignant lymphoma
Wang, L., Qin, W. D., Huo, Y., Li, X., Shi, Q., Rasko, J. E. J., Janin, A., & Zhao, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0113-2 · Cited by 146
Prescott, J. A., & Cook, S. J. (2018) · Cells · doi:10.3390/cells7090115 · Cited by 141
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies
Baik, A. H., Oluwole, O. O., Johnson, D. B., Shah, N., Salem, J.-E., Tsai, K. K., & Moslehi, J. J. (2021) · Circulation Research · doi:10.1161/circresaha.120.315894 · Cited by 138
Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations
Johnson, A. R., Kohli, P. B., Katewa, A., Gogol, E., Belmont, L. D., Choy, R., Penuel, E., Burton, L., Eigenbrot, C., Yu, C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00480 · Cited by 137
Tillman, B. F., Pauff, J. M., Satyanarayana, G., Talbott, M., & Warner, J. L. (2017) · European Journal Of Haematology · doi:10.1111/ejh.13020 · Cited by 138
Dreyling, M. H., Geisler, C., Hermine, O., Kluin‐Nelemans, H. C., Gouill, S. L., Rule, S. A., Shpilberg, O., Walewski, J. A., & Ladetto, M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu264 · Cited by 137
Self-citationGeng, H., Hurtz, C., Lenz, K., Chen, Z., Baumjohann, D., Thompson, S., Goloviznina, N. A., Chen, W., Huan, J., LaTocha, D. H., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.003 · Cited by 141
Self-citationEvolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy
Burger, J. A., & O'Brien, S. M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0037-8 · Cited by 142
Maddocks, K. J., Christian, B. A., Jaglowski, S. M., Flynn, J. M., Jones, J. A., Porcu, P., Wei, L., Jenkins, C., Lozanski, G., Byrd, J. C., et al. (2014) · Blood · doi:10.1182/blood-2014-08-597914 · Cited by 133
Self-citationNordström, L., Sernbo, S., Edén, P., Grønbæk, K., Kolstad, A., Räty, R., Karjalainen, M., Geisler, C. H., Ralfkiaer, E. M., Sundström, C., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12854 · Cited by 133
Kadri, S., Lee, J., Fitzpatrick, C., Galanina, N., Sukhanova, M., Venkataraman, G., Sharma, S., Long, B., Petras, K., Theissen, M., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003632 · Cited by 133
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, B., Bartlett, N. L., Budde, L. E., Caimi, P. F., Chang, J. E., Christian, B. A., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0057 · Cited by 132
Self-citationTargets for Ibrutinib Beyond B Cell Malignancies
Berglöf, A., Hamasy, A., Meinke, S., Palma, M., Krstic, A., Månsson, R., Kimby, E. K., Österborg, A., & Smith, C. I. E. (2015) · Scandinavian Journal of Immunology · doi:10.1111/sji.12333 · Cited by 132
Cinar, M., Hamedani, F. S., Mo, Z., Cinar, B., Amin, H. M., & Alkan, S. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.07.028 · Cited by 130
Gouill, S. L., Morschhauser, F., Chiron, D., Bouabdallah, K. K., Cartron, G., Casasnovas, O., Bodet‐Milin, C., Ragot, S., Bossard, C., Nadal, N., et al. (2020) · Blood · doi:10.1182/blood.2020008727 · Cited by 130
Self-citationRuella, M., Kenderian, S. S., Shestova, O. E., Klichinsky, M., Melenhorst, J. J., Wasik, M. A., Lacey, S. F., June, C. H., & Gill, S. I. (2016) · Leukemia · doi:10.1038/leu.2016.262 · Cited by 132
Bruton’s tyrosine kinase (BTK) as a promising target in solid tumors
Molina‐Cerrillo, J., Alonso‐Gordoa, T., Gajate, P., & Grande, E. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.001 · Cited by 130
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells
Compagno, M., Wang, Q., Pighi, C., Cheong, T.-C., Meng, F.-L., Poggio, T., Yeap, L.-S., Karaca, E., Blasco, R. B., Langellotto, F., et al. (2017) · Nature · doi:10.1038/nature21406 · Cited by 126
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma
Ruan, J., Martin, P., Christos, P. J., Cerchietti, L. C. A., Tam, W., Shah, B. D., Schuster, S. J., Rodriguez, A., Hyman, D. M., Calvo-Vidal, M. N., et al. (2018) · Blood · doi:10.1182/blood-2018-07-859769 · Cited by 124
Self-citationPonader, S., & Burger, J. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1046 · Cited by 126
Jain, P., Kanagal‐Shamanna, R., Zhang, S., Ahmed, M., Ghorab, A., Zhang, L., Ok, C. Y., Li, S., Hagemeister, F. B., Zeng, D., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15567 · Cited by 121
Self-citationvon Tresckow, B., Morschhauser, F., Ribrag, V., Topp, M. S., Chien, C., Seetharam, S., Aquino, R., Kotoulek, S., de Boer, C. J., & Engert, A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1845 · Cited by 125
CAR T-cell therapy for B-cell lymphoma
Denlinger, N., Bond, D. A., & Jaglowski, S. M. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100826 · Cited by 124
Watterson, S. H., Liu, Q., Bertrand, M. B., Batt, D. G., Li, L., Pattoli, M. A., Skala, S., Cheng, L., Obermeier, M. T., Moore, R., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00167 · Cited by 120
Self-citationWaller, E. K., Miklos, D. B., Cutler, C. S., Arora, M., Jagasia, M., Pusic, I., Flowers, M. E. D., Logan, A. C., Nakamura, R., Chang, S., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.06.023 · Cited by 119
Self-citationWang, M. L., Rule, S. A., Zinzani, P. L., Goy, A. H., Casasnovas, O., Smith, S. D., Damaj, G. L., Doorduijn, J. K., Lamy, T., Morschhauser, F., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0575-9 · Cited by 118
Self-citationDavids, M. S., Kim, H. T., Nicotra, A., Savell, A., Francoeur, K., Hellman, J. M., Bazemore, J., Miskin, H. P., Sportelli, P., Stampleman, L. V., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30196-0 · Cited by 117
Small molecules in the treatment of COVID-19
Lei, S., Chen, X., Wu, J., Duan, X., & Men, K. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01249-8 · Cited by 119
Cancer biomarkers for targeted therapy
Liu, D. (2019) · Biomarker Research · doi:10.1186/s40364-019-0178-7 · Cited by 118
Jayappa, K. D., Portell, C. A., Gordon, V. L., Capaldo, B. J., Bekiranov, S., Axelrod, M. J., Brett, L. K., Wulfkuhle, J. D., Gallagher, R. I., Petricoin, E. F., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016004176 · Cited by 120
Self-citationWitzig, T. E., Reeder, C. B., Han, J., LaPlant, B. R., Stenson, M. J., Tun, H. W., Macon, W. R., Ansell, S. M., Habermann, T. M., Inwards, D. J., et al. (2015) · Blood · doi:10.1182/blood-2015-02-629543 · Cited by 114
How I treat CLL patients with ibrutinib
Brown, J. R. (2017) · Blood · doi:10.1182/blood-2017-08-764712 · Cited by 114
Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes
Schiemer, J., Horst, R., Meng, Y., Montgomery, J. I., Xu, Y., Feng, X., Borzilleri, K., Uccello, D. P., Leverett, C., Brown, S., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00686-2 · Cited by 113
Role of the tumor microenvironment in mature B-cell lymphoid malignancies
Fowler, N. H., Cheah, C. Y., Gascoyne, R. D., Gribben, J. G., Neelapu, S. S., Ghia, P., Bollard, C. M., Ansell, S., Curran, M. A., Wilson, W. H., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139493 · Cited by 118
Puente, X. S., Jares, P., & Campo, E. (2018) · Blood · doi:10.1182/blood-2017-10-764373 · Cited by 119
CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
Fischer, J. W., & Bhattarai, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693016 · Cited by 113
Liu, D. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0819-1 · Cited by 112
Bernetti, M., Cavalli, A., & Mollica, L. (2017) · MedChemComm · doi:10.1039/c6md00581k · Cited by 109
Sun, B., Shah, B., Fiskus, W. C., Qi, J., Rajapakshe, K., Coarfa, C., Li, L., Devaraj, S. G. T., Sharma, S., Zhang, L., et al. (2015) · Blood · doi:10.1182/blood-2015-04-639542 · Cited by 110
Self-citationNF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms
Yu, L., Li, L., Medeiros, L. J., & Young, K. H. (2017) · Blood Reviews · doi:10.1016/j.blre.2016.10.001 · Cited by 105
Self-citationNakhoda, S., Vistarop, A., & Wang, Y. L. (2023) · British Journal of Haematology · doi:10.1111/bjh.18418 · Cited by 104
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib
Wodarz, D., Garg, N., Komarova, N. L., Benjamini, O., Keating, M. J., Wierda, W. G., Kantarjian, H. M., James, D. F., O'Brien, S. M., & Burger, J. A. (2014) · Blood · doi:10.1182/blood-2014-02-554220 · Cited by 107
Rule, S. A., Jurczak, W. J., Jerkeman, M., Rusconi, C., Trněný, M., Offner, F. C., Caballero, D. M., Joao, C. M., Witzens‐Harig, M., Hess, G., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0023-2 · Cited by 103
Self-citationClinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer
Smith, S. M., WACHTER, K., Burris, H. A., Schilsky, R. L., George, D. J., Peterson, D. E., Johnson, M. L., Markham, M. J., Mileham, K. F., Beg, M. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03420 · Cited by 107
Owen, C., Berinstein, N. L., Christofides, A., & Sehn, L. H. (2019) · Current Oncology · doi:10.3747/co.26.4345 · Cited by 101
Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials
Burger, J. A. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0188-8 · Cited by 103
Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects
Hershkovitz‐Rokah, O., Pulver, D., Lenz, G., & Shpilberg, O. (2018) · British Journal of Haematology · doi:10.1111/bjh.15108 · Cited by 100
Yun, S., Vincelette, N. D., Acharya, U. H., & Abraham, I. L. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.09.010 · Cited by 100
Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells
Gao, W., Wang, M. L., Wang, L., Lu, H., Wu, S., Dai, B., Ou, Z., Zhang, L., Heymach, J. V., Gold, K. A., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju204 · Cited by 101
Self-citationMYC and therapy resistance in cancer: risks and opportunities
Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 104
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)
Komarova, N. L., Burger, J. A., & Wodarz, D. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409362111 · Cited by 98
AACR Cancer Progress Report 2014
Arteaga, C. L., Adamson, P. C., Engelman, J. A., Foti, M., Gaynor, R. B., Hilsenbeck, S. G., Limburg, P. J., Lowe, S. W., Mardis, E. R., Ramsey, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2123 · Cited by 101
Qiu, Q., Li, C., Song, Y., Shi, T., Luo, X., Zhang, H., Hu, L., Yan, X., Zheng, H., Liu, M., et al. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.05.030 · Cited by 98
Liclican, A. C., Serafini, L., Xing, W., Czerwieniec, G. A., Steiner, B. H., Wang, T., Brendza, K. M., Lutz, J. D., Keegan, K. S., Ray, A. S., et al. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129531 · Cited by 101
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma
Chiron, D., Bellanger, C., Papin, A., Tessoulin, B., Dousset, C., Maïga, S., Moreau, A., Esbelin, J., Trichet, V., Chen‐Kiang, S., et al. (2016) · Blood · doi:10.1182/blood-2016-06-720490 · Cited by 98
Owens, T. D., Brameld, K. A., Verner, E. J., Ton, T. L., Li, X., Zhu, J., Masjedizadeh, M. R., Bradshaw, J. M., Hill, R. J., Tam, D., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01170 · Cited by 97
Cortelazzo, S., Ponzoni, M., Ferreri, A. J. M., & Dreyling, M. H. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.05.001 · Cited by 97
Self-citationHarnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies
Weinstein, S., Toker, I. A., Emmanuel, R., Ramishetti, S., Hazan‐Halevy, I., Rosenblum, D., Goldsmith, M., Avigdor, A., Benjamini, O., Bairey, O., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519273113 · Cited by 97
Contejean, A., Lemiale, V., Resche‐Rigon, M., Mokart, D., Pène, F., Kouatchet, A., Mayaux, J., Vincent, F., Nyunga, M., Bruneel, F., et al. (2016) · Annals of Intensive Care · doi:10.1186/s13613-016-0202-0 · Cited by 95
Molecular Pathogenesis of Mantle Cell Lymphoma
Navarro, A., Beà, S., Jares, P., & Campo, E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.05.002 · Cited by 96
Metadata
- Authors
- Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W. W., Johnson, P., Spurgeon, S. E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J. J., Chang, B. Y., Beaupre, D. M., Kunkel, L. A., & Blum, K. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Derriford Hospital (GB)
- Weill Cornell Medicine (US)
- Hackensack University Medical Center (US)
- University of Wisconsin–Madison (US)
- Jagiellonian University (PL)
- Stanford Medicine (US)
- University of Virginia (US)
- Northwell Health (US)
- Centrum Onkologii (PL)
- University of Manchester (GB)
- University Hospital Ulm (DE)
- LMU Klinikum (DE)
- Cancer Research UK (GB)
- Oregon Health & Science University (US)
- Pharmacyclics (United States) (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- ORCID
- Wang, Michael L.
- Rule, Simon
- Martin, Peter
- Goy, Andre
- Auer, Rebecca
- Kahl, Brad S.
- Jurczak, Wojciech
- Advani, Ranjana H.
- Romaguera, Jorge E.
- Williams, Michael E.
- Barrientos, Jacqueline C.
- Radford, John
- Stilgenbauer, Stephan
- Dreyling, Martin
- Johnson, Peter
- Spurgeon, Stephen E.
- Li, Lei
- Zhang, Liang
- Newberry, Kate
- Fang, Bingliang
- Chang, Betty Y.
- Blum, Kristie A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-08
- Volume
- 369
- Issue
- 6
- Pages
- 507-516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4513941
- OpenAlex
- W2154066874
- Cited by
- 1,685
- References
- 39
- Citations by year
- 2026: 59 · 2025: 67 · 2024: 91 · 2023: 115 · 2022: 142 · 2021: 127 · 2020: 138 · 2019: 127 · 2018: 141 · 2017: 161 · 2016: 133 · 2015: 189 · 2014: 147 · 2013: 42
- FWCI
- 127.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Funders
- American Society of Hematology
- Amgen
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Celgene
- Massachusetts Medical Society
- Les Laboratories Pierre Fabre
- Genentech
- Pharmacyclics
- National Cancer Institute (P30CA014520)
- Janssen Biotech
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- ibrutinib, BTK inhibitors, mantle cell lymphoma, relapsed/refractory lymphoma, bortezomib, B cell receptor signaling, oral BTK inhibitor, overall response rate, progression-free survival, overall survival, adverse events, neutropenia
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Administration, Oral, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Survival Analysis, Lymphocyte Count, Drug Resistance, Neoplasm, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
